Astellas Pharma (4503) Stock Overview

Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAGRAF XL immunosuppressants. The company was founded in 1923 and is headquartered in Tokyo, Japan.

4503 Stock Information

Symbol

4503

Address

2-5-1, Nihonbashi-HonchoTokyo, 103-8411Japan

Founded

Trading hours

Website

https://www.astellas.com

Country

🇯🇵 Japan

Phone Number

81 3 3244 3000

Astellas Pharma (4503) Price Chart

Astellas Pharma Overview: Key Details and Summary

Stock data	2023	Change
Price	$11.56	N/A
Market Cap	$21.03B	N/A
Shares Outstanding	1.82B	-1.61%
Employees	14.48K	N/A
Shareholder Equity	1.51T	3.26%

Valuation	2023	Change
P/E Ratio	0.21	N/A
P/S Ratio	2.02	N/A
P/B Ratio	0.01	N/A
P/FCF	12.82	N/A

Dividends	2023	Change
Dividend Yield	3.27%	N/A
Dividend per share	0.3782	N/A
Dividend Payout Ratio	1.0166	N/A

Growth	2023	Change
ROIC	0.1099	N/A
CAPEX	-249.92M	N/A
Return on Equity	0.0004	N/A

Earnings	2023	Change
Revenue	$10.42B	N/A
Earnings	$677.00M	N/A
Free Cash Flow	$1.64B	N/A
EPS	54.09	N/A
Earnings Yield	4.68	N/A
Gross Margin	0.8101	N/A
Operating Margin	0.0866	N/A
Net income margin	0.065	N/A
FCF Margin	0.1575	N/A

Financial Strength	2023	Change
Total Assets	$16.85B	N/A
Cash on Hand	$2.72B	N/A
Debt to Equity	0.0043	5.33%
Current Ratio	$1.45	7.66%

Other data	2023	Change
Buyback Yield	0.0197	N/A